Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
Status:
Recruiting
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
This is an open-labeled, single-center phase I study in patients with incurable advanced
solid tumors, who failed with all previous standard therapy. The aim is to observe and
evaluate the safety, tolerability, and immunogenicity of LK101 injection.